GotoPER - Physicians' Education Resource
Back to Home
Archived Webcast

Navigating Adjuvant Decision-Making for High-Risk Early-Stage Hormone Receptor-Positive Breast Cancer: An Expert Tumor Board Discussion

Create AccountAlready Registered? Login Here

Release Date

April 20, 2022

Expiration Date

April 21, 2023

Credits

1.5 CME

Specialties

Breast Cancer, New Drugs

Release Date: April 20, 2022

Expiration Date: April 20, 2023

Activity Overview

This online, on-demand, virtual symposium brings together renowned experts in the management of early-stage, hormone receptor–positive/HER2-negative (HR+/HER2-) breast cancer. This multidisciplinary panel of experts engages in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents.

This educational activity is an archive of the live symposium held on April 9, 2022.

Target Audience

This educational activity is directed toward medical oncologists and surgical oncologists who are involved in the management of breast cancer. Other allied health care professionals interested in the management of breast cancer are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate the utility of clinical characteristics, biomarkers, and genomic assays to assess recurrence risk in patients with early-stage, HR+/HER2- breast cancer to identify high-risk patients who may benefit from escalated adjuvant endocrine strategies
  • Explain evidence from clinical trials evaluating CDK4/6 inhibitors in the adjuvant setting for patients with high-risk, early-stage, HR+/HER2- breast cancer
  • Discuss the contribution of surgeons to the shared decision-making process between patients with breast cancer and their multidisciplinary care team with regard to adjuvant therapy options
  • Develop strategies for preventing or managing adverse events associated with escalated adjuvant endocrine therapies for patients with high-risk, early-stage, HR+/HER2- breast cancer, including regimens that incorporate CDK4/6 inhibitors
Navigating Adjuvant Decision-Making for High-Risk Early-Stage Hormone Receptor-Positive Breast Cancer: An Expert Tumor Board Discussion

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

Related Content

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New DecisionsFree CE/CME

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer ManagementFree CE/CME

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBCFree CE/CME

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease ContinuumFree CE/CME

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Course

Navigating Adjuvant Decision-Making for High-Risk Early-Stage Hormone Receptor-Positive Breast Cancer: An Expert Tumor Board Discussion

Create Account